No Data
No Data
Emyria Ltd Advances Mental Health Treatments
Emyria to Raise AU$2.3 Million via Placement
Emyria (ASX:EMD) received commitments to raise AU$2.3 million through a placement of 46 million shares at AU$0.05 apiece, according to a Tuesday filing with the Australian bourse. The issue price rep
Emyria Launches Empax Center
Clinical services and drug development company Emyria (ASX:EMD) launched the Empax Center, a facility dedicated to the delivery and development of new mental health treatments, such as MDMA-assisted t
Emyria's Second Psychiatrist Receives Authorized Prescriber Status From TGA
Clinical services and drug development company Emyria (ASX:EMD) said that its first female psychiatry specialist has been granted authorized prescriber status by Australia's Therapeutic Goods Administ
Emyria Signs Study Agreement for MDMA-Assisted Therapy; Shares Up 7%
Emyria (ASX:EMD) signed a binding research study agreement with charity Reach Wellness to assess the effectiveness of its MDMA-assisted therapy for first responders with post-traumatic stress disorder
Emyria Secures AU$2.5 Million R&D Tax Rebate for Fiscal Year 2023
Emyria (ASX:EMD) secured AU$2.5 million rebate in the fiscal year ended June 30, 2023, from the Australian government's research and development tax incentive scheme. The Australian government encoura
No Data